arrow
A

Adele D'Amico

irccs bambino gesu
H指数:63
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Tolerability of Givinostat: Evidence From Real-World and Clinical Practice

吉维诺stat的安全性和耐受性:来自真实世界和临床实践的依据

2026-04-010
OAAI
Loss of function of retinol dehydrogenase 11 causes a recessive syndrome characterized by myopathy, retinal dystrophy, juvenile cataracts, and microcephaly

视黄醇脱氢酶11功能丧失导致一种隐性综合征,其特征为肌病、视网膜营养不良、青少年白内障和小头畸形。

2026-03-250
PRE
Late-onset Pompe’s disease in pediatrics: results from an Italian national survey on 38 patients and proposal of a targeted diagnostic algorithm

儿科迟发性庞贝病:来自一项意大利全国性调查的38例患者的结果及针对性诊断算法的提出

2025-11-280
OAAI
Muscle transcriptomics of alpha-sarcoglycanopathy highlights inflammatory pathways driving disease

α-肌糖蛋白病的肌肉转录组学研究突出了驱动疾病的炎症通路

Brain
IF11.7
2025-10-280
PRE
Landscape Analysis of COL6A1, COL6A2, and COL6A3 Pathogenic Variants in a Large Italian Cohort Presenting with Collagen VI-Related Myopathies: A Nationwide Report

COL6A1、COL6A2和COL6A3致病性变异在呈现VI型胶原蛋白相关肌病的大型意大利队列中的景观分析:一项全国性报告

2025-10-080
OAAI
Upper limb progression in Duchenne muscular dystrophy: Insights from a 36-month longitudinal study using the PUL 20

杜氏肌营养不良症上肢进展:基于36个月纵向研究使用PUL 20的见解

2025-09-180
OA
Clinical validity of congenital myopathy genes determined by the ClinGen Congenital Myopathies Expert Panel

先天性肌病基因的临床有效性由ClinGen先天性肌病专家小组确定

2025-06-100
PRE
Patients on treatment with risdiplam in Italy: challenges in the interpretation of the real-world data

意大利接受risdiplam治疗的患者的真实世界数据解读挑战

2025-03-281
PRE
Natural history of Becker muscular dystrophy: DMD gene mutations predict clinical severity

贝克肌营养不良的自然史:DMD基因突变预测临床严重程度

BRAIN
IF11.7
2024-11-050
PRE
Association between Reported Sleep Disorders and Behavioral Issues in Children with Myotonic Dystrophy Type 1-Results from a Retrospective Analysis in Italy

1型强直性肌营养不良儿童报告的睡眠障碍与行为问题之间的关联-意大利回顾性分析的结果

2024-09-140
OAAI
Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy

nusinersen治疗的脊髓性肌萎缩症患者的蛋白质组学分析和机器学习

2024-09-101
OAAI
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3

Nusinersen对2型和3型非卧床型脊髓性肌萎缩症患儿呼吸进展的治疗作用

2024-06-014
PRE
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3

未经治疗的2型和3型脊髓性肌萎缩症患者队列中修订的Hammersmith量表中的疾病轨迹

2024-02-275
OAAI